In one of the largest biotech deals this year, Amgen Inc. caught the big fish, so to speak, by reeling in Tularik Inc. with a $1.3 billion takeover bid. (BioWorld Today)
In an ever-changing industry, sometimes a biotech company must sacrifice a valuable asset - its people - for the good of the company. Take a bow, Dr. William Haseltine. (BioWorld Today)
In a deal worth up to $68 million, Structural GenomiX agreed to use its FAST drug discovery technology with Serono SA to develop small-molecule therapeutics. (BioWorld Today)
Neurogen Corp.'s stock rose on Friday, following news that the company entered an agreement to privately sell $100 million worth of common shares. (BioWorld Today)
Less than two months after conducting its initial public offering, GTx Inc. found a potential dream deal for an early clinical program focused on selective androgen receptor modulators (SARMs). (BioWorld Today)
